Using Plasma and Prothrombin Complex Concentrates

Semin Thromb Hemost. 2020 Feb;46(1):32-37. doi: 10.1055/s-0039-1695736. Epub 2019 Sep 19.

Abstract

Surgical patients, following procedural interventions or traumatic injury, often bleed due to ongoing blood loss or coagulopathy. Volume resuscitation and transfusion management are critical for the massively bleeding patient. While transfusions may correct coagulopathy, they carry multiple risks including circulatory overload and transfusion-related acute lung injury. Factor concentrates, specifically prothrombin complex concentrates (PCCs), are often used as part of multimodal therapy for bleeding along with laboratory testing to rapidly assess underlying coagulopathy. Although they are commonly used as part of management algorithms, studies evaluating their efficacy against fresh frozen plasma (FFP) or other potential therapies are needed. Further, PCCs are indicated to treat the coagulopathy associated with non-vitamin K oral anticoagulants in the perioperative setting. The focus of this commentary will be the perioperative use of PCCs, plasma, and FFP.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants* / adverse effects
  • Anticoagulants* / therapeutic use
  • Blood Coagulation Disorders / drug therapy*
  • Blood Coagulation Factors / adverse effects
  • Blood Coagulation Factors / therapeutic use*
  • Blood Component Transfusion*
  • Blood Loss, Surgical / prevention & control*
  • Humans
  • Perioperative Care*
  • Plasma*
  • Transfusion-Related Acute Lung Injury / etiology
  • Transfusion-Related Acute Lung Injury / prevention & control

Substances

  • Anticoagulants
  • Blood Coagulation Factors
  • prothrombin complex concentrates